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Abstract: This work reports the synthesis of three multi-
meric RGD peptidomimetic-paclitaxel conjugates featuring
a number of aVb3 integrin ligands ranging from 2 to 4.
These constructs were assembled by conjugation of the
integrin aVb3 ligand cyclo[DKP-RGD]-CH2NH2 with paclitax-
el via a 2’-carbamate with a self-immolative spacer, the ly-
sosomally cleavable Val-Ala dipeptide linker, a multimeric
scaffold, a triazole linkage, and finally a PEG spacer. Two
monomeric conjugates were also synthesized as reference
compounds. Remarkably, the new multimeric conjugates
showed a binding affinity for the purified integrin aVb3 re-
ceptor that increased with the number of integrin ligands
(reaching a minimum IC50 value of 1.2 nm for the trimeric),
thus demonstrating that multivalency is an effective strat-
egy to strengthen the ligand–target interactions.
Nature makes widespread use of multivalency to create strong
yet reversible interactions. In multivalent interactions, several
covalently linked ligands bind to clustered receptors, with mul-
tiple simultaneous molecular recognition interactions. As a
result, bond reinforcement occurs and strong overall binding is
achieved even when the individual interactions are weak.[1] In
the last decade, multimeric ligands of cancer-overexpressed re-
ceptors have been exploited for different kinds of tumor tar-
geting, such as drug-targeting,[2] imaging,[3] and the use of
’theranostic’ compounds.[4] In this context, multivalency can be
envisaged as a way to improve the tumor-targeting per-
formance of small molecule–drug conjugates (SMDCs), with
the final goal of approaching the efficiency of the antibody–
drug conjugates (ADCs).[5] Indeed, SMDCs possessing multiva-
lent ligands are expected to display enhanced affinity and se-
lectivity for the corresponding tumor receptors, thus promot-
ing more effectively drug accumulation at the diseased tissue.
In recent years, much research effort has been devoted to
the development of SMDCs targeting integrin aVb3,
[6] a trans-
membrane heterodimeric receptor that is overexpressed on
the cell surface of various tumor types (e.g. , melanoma, glio-
blastoma, ovarian, prostatic, and breast cancer).[7] We entered
this research field reporting a low-nanomolar aVb3 integrin
ligand (compound 1 in Figure 1) featuring the Arg-Gly-Asp
(RGD) sequence (i.e. , the binding epitope of the endogenous
ligand for this integrin) connected to a trans-diketopiperazine
(DKP) scaffold.[8] Remarkably, ligand 1 was found to be
33 times more selective for integrin aVb3 with respect to integ-
rin aVb5 in competitive binding assays with biotinylated vitro-
nectin (IC50=4.5:1.1 nm vs. 149:25 nm).[8] Later on, the func-
tionalized ligand cyclo[DKP-RGD]-CH2NH2 (compound 2 in
Figure 1), featuring a primary amino group, was prepared.[9]
The latter compound was conjugated to different payloads,
such as the anticancer drug paclitaxel (PTX, compound 3 in
Figure 1),[9] a pro-apoptotic SMAC (second mitochondria-de-
rived activator of caspases) mimetic compound[10] and an anti-
angiogenic VEGFR-targeting decapentapeptide,[11] by means of
ester and amide linkages. As a further step, to achieve selective
release of PTX in the cancer cell environment, we synthesized
conjugates of the cyclo[DKP-RGD]-CH2NH2 ligand 2 with pacli-
taxel (3) via a 2’-carbamate with a self-immolative spacer and
the lysosomally cleavable linkers (Val-Ala and Phe-Lys dipeptide
sequences).[12] Notably, despite its remarkable size, the cy-
clo[DKP-RGD]-Val-Ala-PTX conjugate 4 (Figure 1) retained a
very good affinity for the aVb3 integrin receptor (IC50=13.3:
3.6 nm in competitive binding assays with biotinylated vitro-
nectin) and displayed fairly effective integrin targeting.[12a]
Herein, we report our initial efforts to exploit multivalency
for increasing the binding affinity of RGD ligands to integrin
aVb3.
[13] Thus, we set to synthesize a series of compounds
(Figure 2) in which PTX is conjugated to one (compounds 5
and 6), two (compound 7), three (compound 8), and four cy-
clo[DKP-RGD] ligands (compound 9), respectively. In this con-
Figure 1. Molecular structures of the aVb3 integrin ligand cyclo[DKP-RGD] 1,
its functionalized analogue 2, the cytotoxic drug paclitaxel (PTX) 3, and the
SMDC cyclo[DKP-RGD]-Val-Ala-PTX 4.
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text, the new conjugates were designed to release PTX intra-
cellularly[14] by means of a self-immolative spacer (PABC-N,N’-di-
methylethylenediamine) and a lysosomally cleavable dipeptide
linker (Val-Ala),[12] which connects PTX to a multivalent scaffold
(Figure 2A). The latter, in turn, is linked to the cyclo[DKP-RGD]
ligand(s) via triazole group(s) deriving from copper-catalyzed
azide-alkyne cycloaddition (CuAAC “click” reaction).[15] To con-
nect the cyclo[DKP-RGD] ligands to the scaffolds, tetraethylene
glycol (PEG-4) spacers were employed in order to make the
conjugates more water-soluble and flexible, which is reported
to facilitate the binding to the receptor (Figure 2A).[16] The
choice of short-sized PEG spacers was made with the aim of
minimizing the formation of bulky loops that can interfere
with binding.[17] With the exception of commercially available
4-pentynoic acid (10) and of the previously reported acid 11,[18]
the alkyne scaffolds used for the synthesis of conjugates 5–9
(Figure 3) are new compounds, whose synthesis and character-
ization are described in the Supporting Information. The syn-
thesis of conjugates 5–9 was carried out according to a
common synthetic strategy, shown in Scheme 1. The bis-pro-
tected compound 15, featuring the Val-Ala linker connected to
the para-aminobenzyl carbamate (PABC)-N,N’-dimethylethyle-
nediamine self-immolative spacer, was prepared according to a
methodology reported by our group.[12a] Compound 15 was
Fmoc-deprotected and the resulting crude free amine was cou-
pled to scaffolds 10–14, affording the corresponding amides
16a–e in good yields (71–92%). Compounds 16a–e were
treated with trifluoroacetic acid for Boc removal and then re-
acted with 2’-(4-nitrophenoxycarbonyl)paclitaxel 17,[12a] afford-
ing carbamates 18a–e again in satisfying yields (66–93%). Fi-
Figure 2. A) General structure of the conjugates. B) Molecular structures of monomeric conjugates (5,6). C) Molecular structures of multimeric conjugates (7–
9).
Figure 3. Mono- and polyalkyne scaffolds used for the preparation of conju-
gates 5–9.
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nally, alkynes 18a–b and polyalkynes 18c–e were subjected to
CuAAC reaction with cyclo[DKP-RGD]-PEG-azide 19, prepared
in two steps from cyclo[DKP-RGD]-CH2NH2 (2) as described in
the Supporting Information. This reaction gave the target com-
pounds 5–9 in good to excellent yields (62%–quantitative).
To assess the effect of ligand multipresentation on conju-
gates’ binding properties, (cyclo[DKP-RGD])n-Val-Ala-PTX (n=1–
4) conjugates 5–9 were examined in vitro for their ability to in-
hibit biotinylated vitronectin binding to the purified aVb3 re-
ceptor and were compared to the unconjugated ligand 1. The
screening assays were performed by incubating the immobi-
lized integrin receptors with solutions of the RGD-PTX conju-
gates at different concentrations (10@12 to 10@5m) in the pres-
ence of biotinylated vitronectin (1 mgmL@1) and measuring the
concentration of bound vitronectin (Figure 4). The IC50 values
are listed in Table 1.
As can be observed in Table 1, conjugates 5 (entry 1) and 6
(entry 2), featuring only one cyclo[DKP-RGD] ligand moiety, dis-
played slightly reduced binding ability (3-fold and 6-fold in-
crease of IC50, respectively) compared to the free ligand 1
(entry 6). To our delight, when the number of cyclo[DKP-RGD]
Scheme 1. Synthesis of (cyclo[DKP-RGD])n-Val-Ala-PTX (n=1, 2, 3, or 4) conjugates 5–9. Reagents and conditions: a) 1) piperidine (5 equiv), DMF, RT, 2 h;
2) acids 10–14 (1.5 equiv), HATU (1.7 equiv), HOAt (1.7 equiv), iPr2NEt (4 equiv), DMF, RT, overnight (16a–16e) ; b) 1) 1:2 TFA/CH2Cl2, 45 min; 2) 17 (1.5 equiv),
iPr2NEt (4 equiv), DMF, RT, overnight; c) 19 (1 equiv) 18a or 18b (1.5 equiv), CuSO4·5H2O (0.5 equiv), sodium ascorbate (0.6 equiv), 1:1 DMF/H2O, 30 8C, over-
night; d) 18c (1 equiv), 19 (3 equiv) CuSO4·5H2O (1 equiv), sodium ascorbate (1.2 equiv), 1:1 DMF/H2O, 30 8C, overnight; e) 18d (1 equiv), 19 (3.6 equiv)
CuSO4·5H2O (1.5 equiv), sodium ascorbate (1.8 equiv), 1:1 DMF/H2O, 30 8C, overnight; f) 18e (1 equiv), 19 (4.8 equiv) CuSO4·5H2O (2 equiv), sodium ascorbate
(2.4 equiv), 1:1 DMF/H2O, 30 8C, overnight.
Figure 4. Inhibition of the binding of biotinylated vitronectin to avb3 integ-
rin. A representative curve was selected for each compound. X-axis shows
the concentration of the tested compounds 1, 5–9 in logarithmic scale; Y-
axis shows the percentage of inhibition of the binding of biotinylated vitro-
nectin in the presence of the tested compounds. Experimental data were
fitted with the software, as described in the Supporting Information.
Table 1. Inhibition of biotinylated vitronectin binding to the avb3 recep-
tor.










3 7 (cyclo[DKP-RGD])2-Val-Ala-PTX 4.0:0.1 3.4
4 8 (cyclo[DKP-RGD])3-Val-Ala-PTX 1.2:0.5 7.6
5 9 (cyclo[DKP-RGD])4-Val-Ala-PTX 1.3:0.3 5.3
6 1 cyclo[DKP-RGD] 4.5:0.1 –
[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of biotinylated vitronectin binding, as estimat-
ed by GraphPad Prism software. All values are the arithmetic mean : the
standard deviation (SD) of triplicate determinations. [b] The relative po-
tency Rp is obtained by dividing the IC50 of the monovalent reference 6
by the IC50 of each multivalent conjugate. Rp/n values were calculated by
dividing Rp of the multivalent conjugates by the valency (n) of each con-
jugate.[22]
Chem. Eur. J. 2017, 23, 14410 – 14415 www.chemeurj.org T 2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim14413
Communication
ligand moieties in the conjugates increases from 1 to 3, a clear
trend of IC50 decrease can be observed (entries 1–2!3!4), to
reach an IC50 lower than that of the free ligand 1 (entry 4 vs.
entry 6). However, with the trimeric conjugate 8 a plateau is
reached (entry 4, Rp/n=7.6), and no further improvement is
obtained when an additional cyclo[DKP-RGD] ligand is present
(conjugate 9, entry 5, Rp/n=5.3). These data demonstrate that
multiple presentation of the integrin ligand leads to a signifi-
cant improvement of the binding affinity,[13] although this
effect seems to be partially balanced by the increasing steric
bulk.
In conclusion, five new conjugates (5–9), featuring a number
of cyclo[DKP-RGD] aVb3 integrin ligands ranging from 1 to 4
have been synthesized using a straightforward modular ap-
proach. Binding tests carried out with the purified receptor of
integrin aVb3 (displacement of biotinylated vitronectin) show
that the IC50 decrease with increasing number of ligand moiet-
ies, down to a plateau reached with the trimeric conjugate 8
(IC50=1.2 nm, Rp/n=7.6). These results demonstrate that mul-
tivalency is a valuable tool to enhance the integrin targeting
performance of this kind of conjugates, and may represent a
possible way to improve the in vivo tumor-targeting properties
of RGD conjugates, which are often suboptimal.[3b,d,h,6e] More-
over, it should be noted that the new ligands are also suitable
for conjugation to different kinds of ’smart’ linkers such as
those amenable to extracellular cleavage[19] (for example, by




methylethylenediamine)carbonyl]oxy]methyl]phenyl] (15)[12] and 2’-
(4-nitrophenoxycarbonyl)paclitaxel (17),[12] were prepared accord-
ing to literature procedures, and their analytical data were in
agreement with those already published. The synthetic procedures
for the preparation of compounds 5–9 and 11–14 are reported in
the Supporting Information, along with the 1H NMR and 13C NMR
spectra, the HPLC traces and HRMS spectra. The inhibition assays
of biotinylated vitronectin binding to the avb3 receptor for com-
pounds 1 and 5–9 are reported in the Supporting Information.
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